The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

Tue, 04th Oct 2022 08:46

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

The FTSE 100 index opened up 73.28 points, 1.1%, at 6,982.04. The FTSE 250 opened up 274.82 points, 1.6%, at 17,558.98 and the AIM All-Share opened up 6.51 points, 0.8% at 815.24.

The Cboe UK 100 opened up 1.3%% at 699.00, the Cboe UK 250 opened up 1.2% at 14,965.48, and the Cboe Small Companies opened 0.1% higher at 12,758.68.

In European equities on Tuesday, the CAC 40 in Paris opened up 2.2%, while the DAX 40 in Frankfurt opened up 2.0%.

Liz Truss has stressed she must take a "responsible" approach to the public finances, as she faces a Cabinet split and a fresh battle with Tory rebels fighting real-terms cuts to benefits.

The prime minister is refusing to rule out a return to austerity or say whether welfare payments will be increased in line with soaring inflation.

Critics who forced a U-turn over the plan to abolish the 45 pence tax rate for top earners are now stepping up pressure on the government to confirm benefits will be raised.

Meanwhile, the Conservative Party Conference continues in Birmingham.

Keynote speeches by Home Secretary Suella Braverman and Foreign Secretary James Cleverly will aim to set out the government's plans on immigration and commitment to support Ukraine.

As discontent brews within the party, Priti Patel is set to accuse Truss and Kwarteng of "spending today with no thought of tomorrow".

"I want to see our party regain its credibility by restoring its commitment to sustainable public spending...which is affordable today, tomorrow and for the foreseeable future," the former home secretary will tell a conference fringe event, according to The Times.

"The UK government's decision to reverse part of its previous tax-cutting plan also had a disproportionately positive effect on sentiment generally, with sterling recouping some of its previously precipitous losses following the initial announcement," interactive investor's Head of Markets Richard Hunter said.

The pound was quoted at USD1.1365 at the London equities open Tuesday, continuing to rise from USD1.1309 at the close on Monday.

Hunter added: "Nonetheless, the longer term impact of the attempt to stimulate growth is yet to be proven, while the government's initial announcement seemed at odds with what the Bank of England is trying to achieve."

In the FTSE 100, Legal & General added 4.7% in early trading.

The financial services firm said it has maintained positive momentum from the first half into the second, "despite market volatility", which has had a "limited economic impact" on the firm. L&G said it expects to deliver annual operating profit growth in line with the 8% seen in the first half.

It said recent "extraordinary" interest rate hikes have been challenging for its pension fund clients and counterparties of its Investment Management liability-driven investment business. However, recent purchases of long-dated gilts by the Bank of England have helped to alleviate the pressure.

Its annuity portfolio continues to perform well, and "has not experienced any difficulty in meeting collateral calls and we have not been forced sellers of gilts or bonds", it said.

L&G estimates a solvency coverage ratio between 235% to 240% as at September 30.

In the FTSE 250, Greggs gained 6.0%.

The pastry chain said total sales were up 15% for the 13 weeks to October 1, and backed its full-year expectations.

It continues to expect around 150 net shop openings in 2022, and left its cost inflation outlook unchanged for the year at around 9%.

"As expected, year-on-year growth moderated in August given the particularly strong 'staycation' effect seen in 2021, however, momentum returned in September. We closed our shops on September 19 for the funeral of Her Majesty The Queen and this impacted reported LFL sales growth for the third quarter by around one percentage point," the food-to-go seller noted.

It acknowledged "considerable" economic uncertainty but expects full-year results to be in line with previous expectations.

Royal Mail rose 3.1%, as its name change to International Distributions Services takes effect. It was first announced back in July.

Wizz Air rose 2.8%, after sharing significant annual growth in September. The budget airline said passengers in the month were up 52% year-on-year to 4.5 million, as capacity rose 37% to 5.3 million.

Ryanair also put in a good performance in the month, with guests rising 49% year-on-year to 15.9 million, and load factor improving to 94% from 81% a year prior. Its shares were up 2.5% in Dublin.

On AIM, N4 Pharma was 12% higher as it reported the successful in vitro testing of Nuvec, its novel delivery system for cancer treatments and vaccines.

Poolbeg Pharma rose 6.0%. The pharmaceutical firm said the US Patent & Trademarks Office has indicated that its patent application "that is directed to the use of POLB 001 and its homologues for the treatment of hypercytokinemia" is allowable.

It expects the formal patent grant in due course, and has filed a continuing application to protect additional claims around this indication.

The euro stood at USD0.9871, up against USD0.9834 at the same time on Monday.

Against the yen, the dollar was trading at JPY144.67, higher compared to JPY144.35 late Monday.

Brent oil was quoted at USD89.38 a barrel at the London equities open Tuesday, up from USD88.30 late Monday.

Gold was quoted at USD1,706.10 an ounce Tuesday, higher against USD1,690.38 at the close on Monday.

Stocks in the Asia Pacific region were stronger on Tuesday. The Nikkei 225 in Tokyo closed up 3.0%, while the S&P/ASX 200 in Sydney ended up 3.8%, after an unexpectedly dovish move from its central bank.

"Australia injected some hope into the region, as its central bank lifted interest rates by just 0.25%, rather less than expected, and prompting wider hopes that other monetary authorities might also consider such a wait and see approach," said ii's Richard Hunter.

In China, financial markets were closed as National Day Golden Week continues.

Still to come in the day's economic calendar, there's EU producer inflation at 1000 BST, and comments from US Federal Reserve officials later in the day.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.